Skip to main content
Premium Trial:

Request an Annual Quote

Merck Licenses Polyplus Transfection Reagent

Premium

France's Polyplus Transfection announced this week that it has signed a deal to provide its proprietary polyethylenimine, or PEI, transfection reagents to Merck.

Under the deal, Merck acquired the rights to the prior use of PEI for transfection, and Polyplus will supply the drug maker with batches of linear PEI transfection reagent to its sites worldwide.

Financial terms of the arrangement were not disclosed.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.